Exeter Financial LLC Buys 225 Shares of CVS Health Co. (NYSE:CVS)

Exeter Financial LLC boosted its holdings in shares of CVS Health Co. (NYSE:CVSFree Report) by 0.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,924 shares of the pharmacy operator’s stock after acquiring an additional 225 shares during the quarter. Exeter Financial LLC’s holdings in CVS Health were worth $2,433,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in CVS Health during the fourth quarter worth $1,092,040,000. Capital International Investors grew its stake in shares of CVS Health by 47.4% in the 4th quarter. Capital International Investors now owns 33,691,698 shares of the pharmacy operator’s stock worth $2,660,298,000 after acquiring an additional 10,837,801 shares in the last quarter. Clearbridge Investments LLC grew its stake in shares of CVS Health by 306.6% in the 4th quarter. Clearbridge Investments LLC now owns 3,046,216 shares of the pharmacy operator’s stock worth $240,529,000 after acquiring an additional 2,297,100 shares in the last quarter. Junto Capital Management LP bought a new stake in shares of CVS Health in the 4th quarter worth $111,209,000. Finally, International Assets Investment Management LLC grew its stake in shares of CVS Health by 8,697.2% in the 4th quarter. International Assets Investment Management LLC now owns 1,322,129 shares of the pharmacy operator’s stock worth $104,395,000 after acquiring an additional 1,307,100 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

CVS Health Price Performance

CVS traded down $2.41 on Thursday, reaching $58.22. The company had a trading volume of 7,393,807 shares, compared to its average volume of 12,013,911. The business has a 50 day simple moving average of $60.00 and a 200 day simple moving average of $70.38. The company has a market cap of $73.09 billion, a price-to-earnings ratio of 10.22, a P/E/G ratio of 0.58 and a beta of 0.53. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.81. CVS Health Co. has a 52-week low of $52.77 and a 52-week high of $83.25.

CVS Health (NYSE:CVSGet Free Report) last announced its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The company had revenue of $88.44 billion during the quarter, compared to analysts’ expectations of $89.33 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the prior year, the business earned $2.20 earnings per share. As a group, sell-side analysts anticipate that CVS Health Co. will post 7.02 EPS for the current year.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Edward J. Ludwig purchased 1,000 shares of CVS Health stock in a transaction on Thursday, May 2nd. The shares were acquired at an average cost of $53.88 per share, for a total transaction of $53,880.00. Following the completion of the transaction, the director now directly owns 21,630 shares of the company’s stock, valued at $1,165,424.40. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on CVS shares. Leerink Partnrs lowered shares of CVS Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 1st. SVB Leerink restated a “market perform” rating and set a $60.00 price target (down previously from $87.00) on shares of CVS Health in a research report on Wednesday, May 1st. Robert W. Baird assumed coverage on shares of CVS Health in a research report on Thursday, May 30th. They set a “neutral” rating and a $61.00 price target for the company. Baird R W upgraded shares of CVS Health to a “hold” rating in a research report on Thursday, May 30th. Finally, Mizuho reduced their price target on shares of CVS Health from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Eleven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and an average target price of $75.05.

View Our Latest Report on CVS Health

About CVS Health

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Read More

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSFree Report).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.